Apligraf pressure sore trials imminent:
This article was originally published in Clinica
Organogenesis is to begin clinical trials in the new year of its Apligraf manufactured skin product to treat pressure sores. The FDA is considering the use of Apligraf, formerly known as Graftskin, in venous ulcers. US studies with diabetic ulcers are underway (see Clinica No 776, p 17). Apligraf is marketed in Canada for venous ulcers by Novartis Pharmaceuticals.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.